Hematological effects of antiviral drugs for Hepatitis C virus
ConclusionsResults support the safety of sofosbuvir-daclatasvir regimen among Egyptians and suggest a significant role of those drug regimens in the treatment of HCV with least adverse events.
Source: QJM - Category: Internal Medicine Source Type: research
More News: Bilirubin | Egypt Health | Hematology | Hepatitis | Hepatitis C | Internal Medicine | Laboratory Medicine | Liver | Liver Disease | Statistics | Study | Urology & Nephrology